Best GLP-1 for Weight Loss: Clinical Matching Guide

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The best GLP-1 for weight loss is not determined by a single "winner," but rather by matching your metabolic profile, clinical history, and individual response factors to available treatment options. Recent clinical data show semaglutide achieves 15–21% weight loss at therapeutic doses, while tirzepatide—which targets dual GLP-1 and GIP receptors—produces 20–27% weight loss in comparable trials, yet individual outcomes vary significantly based on genetic predispositions in appetite and energy metabolism pathways.

Selecting a GLP-1 medication is a personalized wellness decision that benefits from understanding your metabolic baseline and genetic context. PlexusDx integrates precision assessment with licensed compounded options, allowing you to work with providers to evaluate not just which medication might work, but which aligns with your specific metabolic strengths and response profile—moving beyond generic recommendations toward truly precision treatment.

Semaglutide vs. Tirzepatide: Mechanism and Clinical Efficacy Differences

Semaglutide is a GLP-1 receptor agonist that signals fullness and reduces appetite primarily through glucagon-like peptide-1 pathways. In STEP trials, semaglutide 2.4 mg achieved mean weight loss of approximately 15–21% over 68 weeks, with sustained appetite suppression and improved metabolic markers including fasting glucose and triglycerides.

Tirzepatide activates both GLP-1 and GIP receptors, creating a dual-pathway effect on satiety, energy expenditure, and glucose regulation. SUMO trials demonstrated mean weight loss of 20–27% at the 15 mg dose, with some patients experiencing greater metabolic improvements in lipid profiles and insulin sensitivity compared to GLP-1-only therapy. However, higher tirzepatide doses also correlate with increased gastrointestinal side effects in some populations.

Key Metabolic and Genetic Factors That Influence GLP-1 Response

Individual variation in GLP-1 medication response stems from differences in receptor expression, baseline metabolic state, and genetic predispositions in appetite-regulation and energy-balance genes. Understanding your metabolic phenotype—including insulin sensitivity, fasting glucose, lipid profile, and body composition—provides clinical context for provider discussions about which GLP-1 mechanism may be most relevant to your starting point.

The Precision Peptide Genetic Test examines variants in four key genes (GLP1R, GIPR, FTO, MC4R) that govern appetite signaling and metabolic rate, revealing individual predispositions in these pathways. These insights can help contextualize why certain patients respond more robustly to GLP-1 activation, or why dual GIP targeting may align with your genetic profile—though genetic predisposition is not a guarantee of clinical outcome.

Metabolic Factor	Why It Matters for GLP-1 Selection	Clinical Relevance
Baseline Insulin Sensitivity	Lower sensitivity (insulin resistance) may benefit more from dual GIP+GLP-1 effects on glucose handling	Tirzepatide may offer stronger insulin-independent metabolic benefits
GLP1R Gene Variant (rs6923761)	Predisposition to stronger or weaker GLP-1 receptor signaling affects baseline medication sensitivity	May help contextualize expected response magnitude within normal range
FTO Gene Variant (rs9939609)	Associated with appetite-control differences and baseline metabolic rate; informs appetite-suppression pathway strength	Provides context for assessing individual appetite-regulation predisposition
GIP Pathway Status	GIP signaling influences insulin secretion and energy expenditure independent of GLP-1; dual targeting addresses both pathways	Tirzepatide offers GIP activation; semaglutide does not

How to Evaluate GLP-1 Options With Your Healthcare Provider

Before starting any GLP-1, work with your provider to assess baseline metabolic state (fasting glucose, HbA1c, lipid panel), body composition, and presence of comorbidities like type 2 diabetes or hypertension. This clinical baseline enables informed discussion about whether semaglutide (GLP-1 only) or tirzepatide (dual GLP-1/GIP) aligns best with your metabolic priorities and risk profile.

Discuss with your provider whether genetic predispositions in appetite and energy-metabolism genes—revealed through testing like the Precision Peptide Genetic Test—add useful context to your decision. Your provider can interpret whether variants in GLP1R, GIPR, FTO, or MC4R pathways suggest potential response patterns, though genetic predisposition should inform conversation, not dictate choice. Consider also your tolerance for gastrointestinal adaptation and access to compounded or branded formulations within your healthcare plan.

Safety Considerations, Side Effects, and Eligibility for GLP-1 Therapy

GLP-1 medications are not appropriate for all patients. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe gastrointestinal disease, or active pancreatitis. Pregnancy and breastfeeding require discontinuation. Patients with type 1 diabetes or brittle diabetes control may face increased hypoglycemia risk and need careful medical supervision.

Common side effects—nausea, vomiting, constipation, diarrhea—typically emerge during dose escalation and often improve within 2–4 weeks as patients acclimate. Tirzepatide may carry higher risk of GI side effects than semaglutide at equivalent dose levels due to dual-pathway activation. Rare but serious risks include pancreatitis and gallbladder events. Your provider must evaluate your individual risk-benefit profile and monitor you regularly throughout treatment, adjusting dose or choice of agent based on tolerability and efficacy data.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context by revealing your individual predispositions in GLP-1 and GIP receptor genes, appetite-control pathways (FTO), and metabolic rate regulation (MC4R). These insights can support a more informed conversation with your healthcare provider about whether semaglutide's single-pathway mechanism or tirzepatide's dual GLP-1/GIP activation may align with your genetic profile—though genetic predisposition does not predict exact medication response or guarantee clinical outcome.

The genetic test examines variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) to reveal how your body's appetite-signaling and energy-metabolism genes may influence baseline metabolic function and medication response patterns. This is distinct from pharmacogenetic testing; it reveals predispositions in the physiologic pathways that GLP-1 medications target, not how your body metabolizes the drugs themselves. Interpretation should always occur in consultation with your qualified healthcare provider.

If you are considering GLP-1 therapy, the Precision Peptide Genetic Test (available as a $99 add-on or $298 standalone through PlexusDx) can help you and your provider develop a more personalized understanding of your metabolic profile and how genetic factors may contextualize your individual response potential. Combined with clinical baseline assessment (glucose, lipids, body composition) and your provider's clinical judgment, genetic insights can support a more confident, informed decision about whether to pursue semaglutide or tirzepatide, and at what starting dose.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.